This draft guidance, when finalized, will represent the current thinking of the Food and Drug 
Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person 
and is not binding on FDA or the public. You can use an alternative approach if it satisfies the 
requirements of the applicable statutes and regulations. To discuss an alternative approach, contact 
the Office of Generic Drugs. 

 

 

Active Ingredient: Apremilast 

 

Form; Route: Tablet; oral 

 

Recommended Studies: Two studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way, crossover in vivo 

Strength: 30 mg 

Subjects: Normal healthy males and nonpregnant females, general population 

 

______________________________________________________________________________ 

 

2. Type of study: Fed 


Design: Single-dose, two-way crossover in vivo 

Strength: 30 mg 

Subjects: Normal healthy males and nonpregnant females, general population 

 

______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Apremilast in plasma 

 

Bioequivalence based on (90% CI): Apremilast 

 

Waiver request of in vivo testing: 10 mg and 20 mg base strengths based on (i) acceptable 
bioequivalence studies on the 30 mg strength, (ii) proportional similarity of the formulations 
across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths 

 

Dissolution test method and sampling times: The dissolution information for this drug 
product can be found on the FDA-Recommended Dissolution Methods Web site, available to the 
public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. 
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and 
reference products. Specifications will be determined upon review of the application. 

 


